David Shook - 09 Jun 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Medical Officer
Signature
/s/ Charles Newton, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
09 Jun 2025
Net transactions value
$0
Form type
4
Filing time
11 Jun 2025, 17:45:48 UTC
Previous filing
17 Jan 2025
Next filing
11 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shook David Chief Medical Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO /s/ Charles Newton, as Attorney-in-Fact 11 Jun 2025 0001959742

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Award $0 +21,900 $0.000000 21,900 09 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +43,750 $0.000000 43,750 09 Jun 2025 Common Stock 43,750 $12.47 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan ("RSUs"). 25% of the total shares subject to the RSUs will vest on June 9, 2026, and an additional 1/16th of the total shares subject to the RSUs per quarter thereafter, subject to the reporting person providing service through the applicable vesting date.
F2 25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date.